Flotation

Moderna loads up $604m in IPO
Investors including co-founder and Harvard professor Timothy Springer scored exits as mRNA therapy developer Moderna floated in the largest biotech IPO of all time.
Synthorx to synthesise $100m IPO
Synthorx, spun out of Scripps Research Institute, is targeting $100m in a proposed offering half a year after it raised $63m in a series C round backed by Osage University Partners.
Marinomed makes its way to stock exchange
The biopharmaceutical spinout of University of Veterinary Medicine Vienna is issuing 400,000 shares in an initial public offering that is set to fetch between $34m and $41m.
ACSL approaches flotation
Utec-backed Chiba spinout Autonomous Control Systems Laboratory has filed for an initial public offering on the Tokyo Stock Exchange and plans to list on December 21.
Big deal: Orchard harvests $200m IPO
Orchard Therapeutics has listed in the US following a $200m initial public offering that came just three years after the gene therapy developer was spun out of UCL.
Orchard IPO bears $200m of fruit
UCL Technology Fund-backed gene therapy developer Orchard Therapeutics raised $200m in an offering that could possibly close at $230m.
PhaseBio finds $46m in initial public offering
Orphan disease drug developer PhaseBio Pharmaceuticals, which is commercialising research from Duke University, cut the price of its shares sharply pre-offering.
Orchard to orchestrate $173m IPO
The UCL Technology Fund is in line for an exit from gene therapy developer Orchard Therapeutics, which has raised more than $290m in equity funding.

Other News

Sutro seals $86m IPO
Sutro Biopharma, an immunotherapy developer commercialising technology created at Stanford University, has floated on the Nasdaq Global Market.
Principia achieves $122m IPO
Principia Biopharma, whose drug discovery platform is based on research at UCSF, has completed a $122m initial public offering after underwriters exercised their greenshoe option.
Asarina diagnoses listing
Karolinska Development has celebrated an exit as Umeå spinout Asarina Pharma went public in Sweden after raising $16.3m in its initial public offering.
Allogene calls for $100m IPO
The immuno-oncology therapy developer's investors include UC’s office of the chief investment officer, which contributed to a $300m round in January.
Sutro starts IPO proceedings
A month after Sutro closed an $85.4m series E round, the cancer drug developer, based on research at Stanford, has filed for a $75m initial public offering.
Ascentage approaches Hong Kong IPO
Ascentage Pharma, based on research at University of Michigan, has filed to list in Hong Kong having raised about $235m in funding.

Editor's Picks

Big deal: Orchard harvests $200m IPO
Orchard Therapeutics has listed in the US following a $200m initial public offering that came just three years after the gene therapy developer was spun out of UCL.
Big deal: Nucana and Nightstar race to public markets
Nucana, a Scottish Investment Bank-backed cancer treatment developer, and Nightstar Therapeutics, an Oxford spinout focused on retinal gene therapies, have entered the public market.
test reg

Login